MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- NATCO PHARMA
NATCO PHARMA Share Price 
(NTPH)
Here is the latest stock price and chart of Natco Pharma. For more details, see the Natco Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jun 26, 2019 09:23:00 AM | ||
|---|---|---|---|
| Price (Rs)536.60 | Open (Rs) 534.90 | High (Rs) 536.60 | Low (Rs) 530.35 |
| % Change0.43 | Volume 933 | Value (Rs) 500,648 | 52-Week H/L 849.00 / 482.00 |
| Live NSE Quotes | Jun 26, 2019 9:24:58 AM | ||
|---|---|---|---|
| Price (Rs)535.50 | Open (Rs) 530.80 | High (Rs) 538.45 | Low (Rs) 530.80 |
| % Change0.17 | Volume 3,236 | Value (Rs) 1,729,836 | 52-Week H/L 848.30 / 480.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 38.66 | P/E Ratio (x) 13.88 | Market Cap (Rs m) 89,156.09 | P/BV (x) 2.90 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
NATCO PHARMA Share Price Today:
NATCO PHARMA share price is up 0.4% to Rs 536.6 on the BSE. On the NSE, the NATCO PHARMA share price is up 0.2% to Rs 535.5. The total volume of shares traded is 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 0.3%. And the benchmark S&P BSE SENSEX is at 39,446.2 (up 0.0%).
Over the last 30 days, the NATCO PHARMA share price is up 2.2%. And over the last one year, NATCO PHARMA share price is down 33.8%.
|
| |
Today's Market
Indian Indices End Higher, IPO Buzz, and Top Cues in Focus Today(Pre-Open)
On Tuesday, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.
Related Views On News
NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)
Jun 14, 2019Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.
Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)
Jun 21, 2019Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.
This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)
Jun 20, 2019The next big opportunity that has the potential to make you both rich and healthy.
My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)
Jun 19, 2019This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.
MoreTRACK NATCO PHARMA
- Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NATCO PHARMA
NATCO PHARMA 8-QTR ANALYSIS
COMPARE NATCO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.